
11 - 50 employees
Founded 2017
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
Healthcare • Biotechnology • Pharmaceuticals
Akero Therapeutics is a company pioneering novel therapies to transform the lives of people living with serious metabolic diseases. Their flagship program, Efruxifermin (EFX), is aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) and is currently undergoing multiple clinical trials. Akero is committed to advancing medicine in the field of metabolic diseases and has a strong focus on research, development, and clinical studies.
Selected: 🆕 Date Added.
🕒 August 20
Clinical development director advancing Akero’s MASH treatment, efruxifermin, through Phase 3 trials. Leading medical monitoring, regulatory submissions, data analysis, and scientific disclosures.
🏄 California – Remote
💵 $187.1k - $327.5k / year
⏰ Full Time
🔴 Lead
👨⚕️ Medical Director
👻 Ghost score 0%